ARCH Venture Fund XIII, L.P.
SEC insider (Form 3/4/5 filer). CIK 0002006772. 10% Owner at Lyell Immunopharma, Inc. (LYEL). 1 reported Form 4/5 transaction since Sep 2024; latest on Mar 6, 2026. Located in CHICAGO, IL.
Companies ARCH Venture Fund XIII, L.P. has filed insider reports for
- Lyell Immunopharma, Inc. (LYEL): 10% Owner
ARCH Venture Fund XIII, L.P.
CIK: 0002006772
Transaction Breakdown
Open Market Buys (P)1 (100.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)0 (0.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
LYEL
Lyell Immunopharma, Inc.
10% Owner